Insulet Share Price (NASDAQ: PODD)

$330.88

▲

3.03

(0.92%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Insulet Stock chart to analyse performance

Insulet stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$330.88
Today's High:$332.38
$330.88
0.0%
Downside
Day's Volatility :0.45%
Upside
0.45%
52 Weeks Low:$180.31
52 Weeks High:$334.18
$330.88
45.51%
Downside
52 Weeks Volatility :46.04%
Upside
0.99%

Insulet Stock Returns

Period	Insulet Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	1.12%	6.0%	0.0%
6 Months	16.52%	-5.6%	0.0%
1 Year	78.51%	-11.1%	0.0%
3 Years	20.68%	6.8%	-7.8%

Insulet Corporation Key Stats

Check Insulet key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$327.85
Open	$331.95
Today's High	$332.38
Today's Low	$330.88
Market Capitalization	$23.1B
Today's Volume	$499.5K
52 Week High	$334.18
52 Week Low	$180.31
Revenue TTM	$2.4B
EBITDA	$475.8M
Earnings Per Share (EPS)	$3.26
PE Ratio	100.57
Profit Margin	10.01%
Quarterly Earnings Growth YOY	-0.88%
Return On Equity TTM	19.18%

Stock Returns calculator for Insulet Stock including INR - Dollar returns

The Insulet stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Insulet investment value today

Current value as on today

₹1,83,131

Returns

₹83,131

(+83.13%)

Returns from Insulet Stock

₹78,815 (+78.82%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Insulet Stock

250%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Search interest for Insulet Stock from India on INDmoney has increased by 250% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Insulet Stock

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	569	-0.60	0.04%

Global Institutional Holdings in Insulet Corporation

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
12.37%
FMR Inc
11.25%
BlackRock Inc
9.10%
Capital Research Global Investors
6.73%
State Street Corp
4.30%
Baillie Gifford & Co Limited.
3.03%

Analyst Recommendation on Insulet Stock

Rating

Trend

Buy

82%Buy

17%Hold

0%Sell

Based on 28 Wall street analysts offering stock ratings for Insulet(by analysts ranked 0 to 5 stars)

Insulet Share Price Target

What analysts predicted

Upside of 6.8%

Target:

$353.39

Current:

$330.88

Insulet share price target is $353.39, a slight Upside of 6.8% compared to current price of $330.88 as per analysts' prediction.

Insulet Stock Insights

Price Movement
In the last 1 year, PODD stock has moved up by 78.5%
Increasing Revenue
Revenue is up for the last 2 quarters, 569.0M → 649.1M (in $), with an average increase of 12.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 100.7M → 22.5M (in $), with an average decrease of 50.6% per quarter
PODD vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 159.8% return, outperforming this stock by 132.7%

Insulet Corporation Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$738.2M	↑ 30.93%
Net Income	$11.6M	↑ 252.37%
Net Profit Margin	1.57%	↑ 0.99%

	FY20	Y/Y Change
Revenue	$904.4M	↑ 22.51%
Net Income	$6.8M	↓ 41.38%
Net Profit Margin	0.75%	↓ 0.82%

	FY21	Y/Y Change
Revenue	$1.1B	↑ 21.49%
Net Income	$16.8M	↑ 147.06%
Net Profit Margin	1.53%	↑ 0.78%

	FY22	Y/Y Change
Revenue	$1.3B	↑ 18.79%
Net Income	$4.6M	↓ 72.62%
Net Profit Margin	0.35%	↓ 1.18%

	FY23	Y/Y Change
Revenue	$1.7B	↑ 30.02%
Net Income	$206.3M	↑ 4384.78%
Net Profit Margin	12.16%	↑ 11.81%

	FY24	Y/Y Change
Revenue	$2.1B	↑ 22.07%
Net Income	$418.3M	↑ 102.76%
Net Profit Margin	20.19%	↑ 8.03%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$441.7M	↓ 13.36%
Net Income	$51.5M	↓ 50.15%
Net Profit Margin	11.66%	↓ 8.6%

	Q2 FY24	Q/Q Change
Revenue	$488.5M	↑ 10.6%
Net Income	$188.6M	↑ 266.21%
Net Profit Margin	38.61%	↑ 26.95%

	Q3 FY24	Q/Q Change
Revenue	$543.9M	↑ 11.34%
Net Income	$77.5M	↓ 58.91%
Net Profit Margin	14.25%	↓ 24.36%

	Q4 FY24	Q/Q Change
Revenue	$597.5M	↑ 9.85%
Net Income	$100.7M	↑ 29.94%
Net Profit Margin	16.85%	↑ 2.6%

	Q1 FY25	Q/Q Change
Revenue	$569.0M	↓ 4.77%
Net Income	$35.4M	↓ 64.85%
Net Profit Margin	6.22%	↓ 10.63%

	Q2 FY25	Q/Q Change
Revenue	$649.1M	↑ 14.08%
Net Income	$22.5M	↓ 36.44%
Net Profit Margin	3.47%	↓ 2.75%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$480.3M	↑ 29.75%

	FY20	Y/Y Change
Profit	$582.3M	↑ 21.24%

	FY21	Y/Y Change
Profit	$752.1M	↑ 29.16%

	FY22	Y/Y Change
Profit	$805.6M	↑ 7.11%

	FY23	Y/Y Change
Profit	$1.2B	↑ 43.98%

	FY24	Y/Y Change
Profit	$1.4B	↑ 24.64%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$306.8M	↓ 15.06%

	Q2 FY24	Q/Q Change
Profit	$330.9M	↑ 7.86%

	Q3 FY24	Q/Q Change
Profit	$377.1M	↑ 13.96%

	Q4 FY24	Q/Q Change
Profit	$430.9M	↑ 14.27%

	Q1 FY25	Q/Q Change
Profit	$409.0M	↓ 5.08%

	Q2 FY25	Q/Q Change
Profit	$452.3M	↑ 10.59%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$98.4M	↑ 174.1%
Investing Cash Flow	$-73.6M	↓ 60.11%
Financing Cash Flow	$73.5M	↓ 948.24%

	FY20	Y/Y Change
Operating Cash Flow	$84.0M	↓ 14.63%
Investing Cash Flow	$14.0M	↓ 119.02%
Financing Cash Flow	$605.5M	↑ 723.81%

	FY21	Y/Y Change
Operating Cash Flow	$-68.1M	↓ 181.07%
Investing Cash Flow	$-82.7M	↓ 690.71%
Financing Cash Flow	$40.7M	↓ 93.28%

	FY22	Y/Y Change
Operating Cash Flow	$119.0M	↓ 274.74%
Investing Cash Flow	$-191.1M	↑ 131.08%
Financing Cash Flow	$-40.3M	↓ 199.02%

	FY23	Y/Y Change
Operating Cash Flow	$145.7M	↑ 22.44%
Investing Cash Flow	$-119.4M	↓ 37.52%
Financing Cash Flow	$-13.6M	↓ 66.25%

	FY24	Y/Y Change
Operating Cash Flow	$430.3M	↑ 195.33%
Investing Cash Flow	$-146.2M	↑ 22.45%
Financing Cash Flow	$-28.1M	↑ 106.62%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$87.6M	↑ 95.1%
Investing Cash Flow	$-24.0M	↓ 24.05%
Financing Cash Flow	$-14.1M	↓ 740.91%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$96.5M	↑ 10.16%
Investing Cash Flow	$-24.9M	↑ 3.75%
Financing Cash Flow	$-900.0K	↓ 93.62%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$98.5M	↑ 2.07%
Investing Cash Flow	$-29.3M	↑ 17.67%
Financing Cash Flow	$7.8M	↓ 966.67%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$147.7M	↑ 49.95%
Investing Cash Flow	$-68.0M	↑ 132.08%
Financing Cash Flow	$-20.9M	↓ 367.95%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$63.8M	↓ 56.8%
Investing Cash Flow	$-15.7M	↓ 76.91%
Financing Cash Flow	$277.8M	↓ 1429.19%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$196.5M	↑ 207.99%
Investing Cash Flow	$-23.2M	↑ 47.77%
Financing Cash Flow	$-343.6M	↓ 223.69%

Insulet Technicals Summary

Sell

Neutral

Buy

Insulet is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Insulet Corporation Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Insulet Corporation	15.26%	16.52%	78.51%	20.68%	57.32%
Medtronic Plc	0.43%	2.83%	4.95%	3.85%	-7.4%
Edwards Lifesciences Corp.	7.86%	12.37%	15.35%	-13.9%	3.87%
Boston Scientific Corp.	-0.06%	1.69%	34.08%	157.96%	172.6%
Stryker Corporation	-0.64%	1.6%	11.55%	85.46%	108.86%
Abbott Laboratories	5.51%	-1.77%	17.63%	25.72%	30.74%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Insulet Corporation	100.57	100.57	4.61	4.65	0.19	0.08	NA	20.78
Medtronic Plc	25.17	25.17	2.19	5.46	0.1	0.04	0.03	37.46
Edwards Lifesciences Corp.	33.96	33.96	4.86	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.63	62.63	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.04	51.04	2.23	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.56	16.56	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Insulet Corporation	Buy	$23.1B	57.32%	100.57	10.01%
Medtronic Plc	Buy	$116.7B	-7.4%	25.17	13.63%
Edwards Lifesciences Corp.	Buy	$47.6B	3.87%	33.96	72.96%
Boston Scientific Corp.	Buy	$155.9B	172.6%	62.63	13.55%
Stryker Corporation	Buy	$147.1B	108.86%	51.04	12.25%
Abbott Laboratories	Buy	$229.7B	30.74%	16.56	32.43%

About Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Organization	Insulet
Employees	3900
CEO	Ms. Ashley A. McEvoy
Industry	Health Technology

Key Management of Insulet Corporation

Name	Title
Ms. Ana Maria Chadwick	Executive VP & CFO
Mr. John Wodick Kapples J.D.	Senior VP & General Counsel
Mr. Eric Benjamin	Executive VP, Chief Product & Customer Experience Officer
Ms. Ashley A. McEvoy	CEO, President & Director
Mr. Prem Singh	Senior Vice President of Global Operations
Mr. Amit Guliani	Interim CTO & Group VP of Customer-Facing Software Engineering
June Lazaroff	Senior Director of Investor Relations
Ms. Laetitia Cousin	Senior VP of Regulatory Affairs, Quality Assurance & Compliance
Ms. Angela Geryak Wiczek	Senior Director of Corporate Communications
Mr. Philip Hildale	Senior Vice President of Sales & Customer Care

Important FAQs about investing in PODD Stock from India :

What is Insulet share price today?

Insulet share price today is $330.88 as on August 23, 2025 at 1:29 AM IST at the close of the market. Insulet share today touched a day high of $332.38 and a low of $330.88.

What is the 52 week high and 52 week low for Insulet share?

Insulet share touched a 52 week high of $334.18 and a 52 week low of $180.31. Insulet stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $330.88, lower by 0.99% versus the 52 week high.

How to invest in Insulet Stock (PODD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Insulet on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Insulet Shares that will get you 0.0045 shares as per Insulet share price of $330.88 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Insulet Stock (PODD) from India?

Indian investors can start investing in Insulet (PODD) shares with as little as ₹87.521 or $1 (as of August 23, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Insulet stock (as per the Rupee-Dollar exchange rate as on August 23, 2025). Based on Insulet share’s latest price of $330.88 as on August 23, 2025 at 1:29 AM IST, you will get 0.0302 shares of Insulet. Learn more about fractional shares .

What are the returns that Insulet has given to Indian investors in the last 5 years?

Insulet stock has given 57.32% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?